Authors:
A. Castan1, S. Cruz Ciria1, C. García Mur2, A. García Gámez1, D. Marquina Martínez1, S. Hakim Alonso1; 1Zaragoza/ES, 2ES
DOI:
10.1594/seram2014/S-1231
Bibliografía
1.Lobbes MB,
Prevos R,
Smidt M,
Tjan-Heijnen VC,
van Goethem M,
Schipper R,
et al.
The role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy: a systematic review.
Insights Imaging.
2013;4:163-75.2.Ko ES,
Han BK,
Kim RB,
Ko EY,
Shin JH,
Hahn SY,
et al.
Analysis of factors that influence the accuracy of magnetic resonance imaging for predicting response after neoadjuvant chemotherapy in locally advanced breast cancer.
.Ann Surg Oncol.
2013;20:2562-8.3.Chen JH,
Bahri S,
Mehta RS,
Kuzucan A,
Yu HJ,
Carpenter PM,
et al.
Breast cancer: evaluation of response to neoadjuvant chemotherapy with 3.0-T MR imaging.
Radiology.
2011;261:735-43.4.Kwong MS,
Chung GC,
Horvath LJ,
Ward BA,
Hsu AD,
Carter D,
et al.
Postchemotherapy MRI overestimates residual disease compared with histopathology in responders to neoadjuvant therapy for locally advanced breast cancer.
Cancer J.
2006;12:212-21.